Belite Bio Wins FDA Priority Review for Tinlarebant in Stargardt Disease

Key Points

• FDA priority review granted: The FDA accepted Belite Bio’s application for tinlarebant to treat Stargardt disease type 1 and set a Feb. 12, 2027, PDUFA decision date. If approved, it would be the first approved treatment for the rare inherited retinal disease.
• Phase III results showed disease-progression benefits: In the DRAGON trial, once-daily tinlarebant slowed retinal lesion growth by about 35.7% versus placebo, while maintaining an approximately 80% reduction in RBP4 levels. Common eye-related side effects included temporary yellow-tinted vision and delayed dark adaptation; no serious ocular treatment-related events were reported.
• Belite is preparing for a potential commercial launch: The company is building U.S. sales, physician-education, payer-access and patient-support infrastructure, estimating roughly 53,000 U.S. patients have Stargardt disease type 1, including about 20,000 clinically diagnosed individuals.

Belite Bio NASDAQ: BLTE said the U.S. Food and Drug Administration has accepted its new drug application for tinlarebant as a treatment for Stargardt disease type 1, granted the application priority review and set a Feb. 12, 2027, PDUFA date.

At the company’s 2026 Commercial Day, Chairman and CEO Tom Lin said a potential approval would represent a transition for Belite into a commercial-stage biotechnology company. The company is preparing U.S. launch infrastructure, physician education, market-access initiatives and patient-support services while the application remains under FDA review.

“If approved, tinlarebant will be the first and only approved treatment for Stargardt disease type 1,” Lin said. No treatment has yet been approved for the progressive inherited retinal disease.

Stargardt Disease Burden and Diagnosis

Stargardt disease type 1, also called ABCA4-associated retinal dystrophy, is a rare inherited disease that progressively damages central vision while often leaving peripheral vision relatively intact. Michel Michaelides, consultant ophthalmologist at Moorfields Eye Hospital, said the condition is caused by disease-causing variants in the ABCA4 gene, which disrupts removal of vitamin A byproducts from photoreceptors. The resulting accumulation of toxic compounds can lead to retinal pigment epithelium and photoreceptor dysfunction and cell death.

Patients speaking during the event described challenges including difficulty reading, recognizing faces, navigating public places, preparing food and traveling independently. They also cited the loss of driving ability and emotional strain associated with progressive vision impairment.

Paul Bernstein, an inherited retinal disease specialist at the Moran Eye Center of the University of Utah, said patients are typically referred from optometrists or general ophthalmologists to inherited retinal disease specialists, who conduct imaging and genetic testing to confirm the diagnosis and rule out conditions that can resemble Stargardt disease.

Current management largely consists of supportive measures, including low-vision aids, counseling, UV-blocking eyewear and avoiding high-dose vitamin A supplements, Bernstein said. He added that these steps do not alter the disease’s progression.

DRAGON Trial Results

Michaelides reviewed results from the Phase III DRAGON trial, a randomized, double-masked, placebo-controlled study of once-daily oral tinlarebant in adolescents ages 12 to 20 with Stargardt disease. Participants were assigned tinlarebant 5 milligrams daily or placebo in a 2:1 ratio.

The study’s primary endpoint was the annualized growth rate in the area of definitely decreased autofluorescence, or DDAF, a retinal imaging measure of atrophy. According to the presentation, tinlarebant slowed DDAF lesion growth by approximately 35.7% compared with placebo, with a p-value of 0.0033 under one statistical model. Annual lesion growth was reported at 0.38 square millimeters for tinlarebant versus 0.59 square millimeters for placebo.

The drug also slowed growth in total decreased autofluorescence, or DAF, by 33.7% versus placebo, according to Michaelides. Best-corrected visual acuity did not significantly change in either treatment group over two years, which Michaelides said was consistent with the disease’s natural history and the limitations of visual-acuity measurement over relatively short periods.

Tinlarebant produced a sustained reduction of about 80% in retinol-binding protein 4, or RBP4, during treatment, according to the company’s presentation. RBP4 levels returned toward baseline after treatment ended.

The most commonly cited treatment-related eye-related adverse events were xanthopsia, a temporary yellow tint to vision, and delayed dark adaptation. Michaelides said most such events were mild and often resolved while patients remained on treatment. The presentation reported no serious ocular treatment-emergent adverse events.

Commercial Preparations and Market Access

Chief Commercial Officer Kelly Kilpatrick said Belite estimates that about 53,000 people in the U.S. are living with Stargardt disease type 1, including roughly 20,000 who have been clinically diagnosed. The company estimates that about half of those diagnosed patients have received confirmatory genetic testing.

Belite’s commercial strategy centers on four areas:

• Increasing disease awareness and education on inherited retinal disease genetic testing;
• Working with payers on access, formulary coverage and reimbursement;
• Supporting post-approval physician adoption through field teams and digital marketing; and
• Providing patient services, affordability programs and specialty-pharmacy support.

Kilpatrick said the company expects to deploy at least 50 customer-facing personnel after a potential approval. Retina and inherited retinal disease specialists are expected to be the initial primary prescribers, while ophthalmologists and optometrists may help identify, refer and support patients.

The company anticipates that payers may require confirmatory ABCA4 genetic testing for coverage, although Kilpatrick said final requirements will depend on the FDA label and payer policies. She said genetic testing can be accessed through multiple testing programs and commercial laboratories, with results generally returned to the ordering healthcare provider within three to four weeks after sample receipt.

During the question-and-answer session, Belite executives and physician speakers said they expect interest in therapy to extend across disease stages, including among patients with more advanced vision loss, subject to the final label and physician judgment. They also suggested treatment could be used long term, though DRAGON provided two years of treatment data.

Belite said it is conducting payer engagement and building patient-support and reimbursement infrastructure ahead of the FDA’s decision date.

About Belite Bio (NASDAQ:BLTE)

Belite Bio, Inc NASDAQ: BLTE is a clinical-stage biotechnology company focused on discovering and developing small molecule therapeutics for metabolic and inflammatory diseases. Leveraging a proprietary drug-discovery platform, the company aims to address conditions such as nonalcoholic steatohepatitis (NASH) and obesity by targeting pathways involved in fibrosis, inflammation and metabolic regulation.

Belite Bio’s pipeline includes multiple candidates in preclinical and early clinical development stages.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source